146 related articles for article (PubMed ID: 11781646)
1. Phase II trial of high-dose intravenous doxorubicin, etoposide, and cyclophosphamide with autologous stem cell support in patients with residual or responding recurrent ovarian cancer.
Morgan RJ; Doroshow JH; Leong L; Schriber J; Shibata S; Forman S; Hamasaki V; Margolin K; Somlo G; Alvarnas J; McNamara M; Longmate J; Raschko J; Chow W; Vasilev S; McGonigle K; Yen Y
Bone Marrow Transplant; 2001 Nov; 28(9):859-63. PubMed ID: 11781646
[TBL] [Abstract][Full Text] [Related]
2. High-dose topotecan, melphalan, and cyclophosphamide (TMC) with stem cell support: a new regimen for the treatment of advanced ovarian cancer.
Donato ML; Gershenson DM; Wharton JT; Ippoliti CM; Aleman AS; Bodurka-Bevers D; Bevers MW; Burke TW; Levenback CF; Wolf JK; Freedman RS; Bast RC; Gajewski JL; Champlin RE
Gynecol Oncol; 2001 Sep; 82(3):420-6. PubMed ID: 11520135
[TBL] [Abstract][Full Text] [Related]
3. Serial intense chemotherapy combining topotecan, etoposide, carboplatin and cyclophosphamide (TECC) followed by autologous hematopoietic stem cell support in patients with high risk soft tissue sarcoma (STS).
Bernbeck B; Bahci S; Meisel R; Troeger A; Schönberger S; Laws HJ; Kramm C; Wessalowski R; Koscielniak E; Dilloo D; Göbel U
Klin Padiatr; 2007; 219(6):318-22. PubMed ID: 18050041
[TBL] [Abstract][Full Text] [Related]
4. A phase I-II study of high-dose melphalan, mitoxantrone and carboplatin with peripheral blood stem cell support in patients with advanced ovarian or breast carcinoma.
Weaver CH; Greco FA; Hainsworth JD; Zhen B; Baldwin P; Wittlin F; Lewis M; West WH; Schwartzberg L; Buckner CD
Bone Marrow Transplant; 1997 Nov; 20(10):847-53. PubMed ID: 9404925
[TBL] [Abstract][Full Text] [Related]
5. Treatment of relapsed aggressive lymphomas: regimens with and without high-dose therapy and stem cell rescue.
Hagemeister FB
Cancer Chemother Pharmacol; 2002 May; 49 Suppl 1():S13-20. PubMed ID: 12042984
[TBL] [Abstract][Full Text] [Related]
6. Dose-intensive therapy for extensive-stage small cell lung cancer and extrapulmonary small cell carcinoma: long-term outcome.
Elias AD; Skarin AT; Richardson P; Ibrahim J; McCauley M; Frei E
Biol Blood Marrow Transplant; 2002; 8(6):326-33. PubMed ID: 12108918
[TBL] [Abstract][Full Text] [Related]
7. Long-term results of first-line sequential high-dose etoposide, ifosfamide, and cisplatin chemotherapy plus autologous stem cell support for patients with advanced metastatic germ cell cancer: an extended phase I/II study of the German Testicular Cancer Study Group.
Schmoll HJ; Kollmannsberger C; Metzner B; Hartmann JT; Schleucher N; Schöffski P; Schleicher J; Rick O; Beyer J; Hossfeld D; Kanz L; Berdel WE; Andreesen R; Bokemeyer C;
J Clin Oncol; 2003 Nov; 21(22):4083-91. PubMed ID: 14568987
[TBL] [Abstract][Full Text] [Related]
8. High dose chemotherapy followed by autologous haemopoietic stem cell transplant in multiple myeloma.
Kumar L; Raju GM; Ganessan K; Shawgi S; Menon H; Wadhwa J; Sharma A; Singh R; Kochupillai V
Natl Med J India; 2003; 16(1):16-21. PubMed ID: 12715951
[TBL] [Abstract][Full Text] [Related]
9. Randomized comparison of granulocyte colony-stimulating factor versus granulocyte-macrophage colony-stimulating factor plus intensive chemotherapy for peripheral blood stem cell mobilization and autologous transplantation in multiple myeloma.
Arora M; Burns LJ; Barker JN; Miller JS; Defor TE; Olujohungbe AB; Weisdorf DJ
Biol Blood Marrow Transplant; 2004 Jun; 10(6):395-404. PubMed ID: 15148493
[TBL] [Abstract][Full Text] [Related]
10. Cyclophosphamide, etoposide and carboplatine plus non-cryopreserved autologous peripheral blood stem cell transplantation rescue for patients with refractory or relapsed non-Hodgkin's lymphomas.
Mabed M; Al-Kgodary T
Bone Marrow Transplant; 2006 Apr; 37(8):739-43. PubMed ID: 16501587
[TBL] [Abstract][Full Text] [Related]
11. High-dose melphalan-based chemotherapy and autologous stem cell transplantation after second look laparotomy in patients with chemosensitive advanced ovarian carcinoma: long-term results.
Bertucci F; Viens P; Delpero JR; Bardou VJ; Faucher C; Houvenaeghel G; Maraninchi D
Bone Marrow Transplant; 2000 Jul; 26(1):61-7. PubMed ID: 10918406
[TBL] [Abstract][Full Text] [Related]
12. Phase II trial of intraperitoneal cisplatin with intravenous doxorubicin and cyclophosphamide in previously untreated patients with advanced ovarian cancer-long-term follow-up.
Morgan RJ; Braly P; Cecchi G; Leong L; Shibata S; Margolin K; Somlo G; McNamara M; Longmate J; Schinke S; Raschko J; Nagasawa S; Kogut N; Parker P; Stein A; Cho J; Smith E; Coluzzi P; Najera L; Johnson D; Womack E; Doroshow JH
Gynecol Oncol; 1999 Dec; 75(3):419-26. PubMed ID: 10600300
[TBL] [Abstract][Full Text] [Related]
13. Multiple cycles of dose-intensive chemotherapy with repeated stem cell support as induction treatment in metastatic breast cancer: a feasibility study.
García-Rayo S; Pérez-Calvo J; Martín-Algarra S; Martínez-Monge R; Fernández-Hidalgo O; Subirá L; Martínez-Aguillo M; Rebollo J; Azinovic I; Brugarolas A
Bone Marrow Transplant; 2001 Aug; 28(3):235-42. PubMed ID: 11535990
[TBL] [Abstract][Full Text] [Related]
14. Efficacy of consolidation high-dose chemotherapy with ifosfamide, carboplatin and etoposide (HD-ICE) followed by autologous peripheral blood stem cell rescue in chemosensitive patients with metastatic soft tissue sarcomas.
Schlemmer M; Wendtner CM; Falk M; Abdel-Rahman S; Licht T; Baumert J; Straka C; Hentrich M; Salat C; Hiddemann W; Issels RD
Oncology; 2006; 71(1-2):32-9. PubMed ID: 17344669
[TBL] [Abstract][Full Text] [Related]
15. Randomized trial of high-dose chemotherapy and autologous hematopoietic stem cell support for high-risk primary breast carcinoma: follow-up at 12 years.
Hanrahan EO; Broglio K; Frye D; Buzdar AU; Theriault RL; Valero V; Booser DJ; Singletary SE; Strom EA; Gajewski JL; Champlin RE; Hortobagyi GN
Cancer; 2006 Jun; 106(11):2327-36. PubMed ID: 16639731
[TBL] [Abstract][Full Text] [Related]
16. Phase III trial of high-dose sequential chemotherapy with peripheral blood stem cell support compared with standard dose chemotherapy for first-line treatment of advanced ovarian cancer: intergroup trial of the AGO-Ovar/AIO and EBMT.
Möbus V; Wandt H; Frickhofen N; Bengala C; Champion K; Kimmig R; Ostermann H; Hinke A; Ledermann JA; ;
J Clin Oncol; 2007 Sep; 25(27):4187-93. PubMed ID: 17698804
[TBL] [Abstract][Full Text] [Related]
17. Busulfan, cyclophosphamide, and etoposide as high-dose conditioning regimen in patients with malignant lymphoma.
Hänel M; Kröger N; Sonnenberg S; Bornhäuser M; Krüger W; Kroschinsky F; Hänel A; Metzner B; Birkmann J; Schmid B; Hoffknecht MM; Fiedler F; Ehninger G; Zander AR
Ann Hematol; 2002 Feb; 81(2):96-102. PubMed ID: 11907790
[TBL] [Abstract][Full Text] [Related]
18. Randomized Phase II trial of two high-dose chemotherapy regimens with stem cell transplantation for the treatment of advanced ovarian cancer in first remission or chemosensitive relapse: a Southwest Oncology Group study.
Stiff PJ; Shpall EJ; Liu PY; Wilczynski SP; Callander NS; Scudder SA; Jazieh AR; Samlowski W; McCoy J; Alberts DS;
Gynecol Oncol; 2004 Jul; 94(1):98-106. PubMed ID: 15262126
[TBL] [Abstract][Full Text] [Related]
19. Efficacy and hematologic toxicity of salvage chemotherapy following stem cell-supported high-dose chemotherapy in women with recurrent ovarian cancer.
Cook S; Penson R; Duska L; Nikrui N; Goodman A; Fuller A; Seiden M
Gynecol Oncol; 2000 Apr; 77(1):48-54. PubMed ID: 10739690
[TBL] [Abstract][Full Text] [Related]
20. High-dose ifosfamide and etoposide with filgrastim for stem cell mobilization in patients with advanced ovarian cancer.
Donato ML; Gershenson D; Ippoliti C; Wharton JT; Bast RC; Aleman A; Anderlini P; Gajewski JG; Giralt S; Molldrem J; Ueno N; Lauppe J; Korbling M; Boyer J; Bodurka-Bevers D; Bevers M; Burke T; Freedman R; Levenback C; Wolf J; Champlin RE
Bone Marrow Transplant; 2000 Jun; 25(11):1137-40. PubMed ID: 10849525
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
